Sage braces for make-or-break depression data

On Tuesday, Sage Therapeutics found that investors aren't so concerned about its sales and revenue. At least, not right now.

Rather, the main focus of Sage's first quarter earnings report was an experimental drug that may provide a major lift to the company's business later on. Important data that could help the drug get approved as a treatment for major depressive disorder, or MDD, are expected soon.